REFERENCES
1. Rawshani A., Rawshani A., Franzén S., et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017; 376: 1407–18.
2. Lau L., Lew J., Borschmann K., et al. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 2019; 10 (3): 780–92. DOI: https://doi.org/10.1111/jdi.12932
3. O’Donnell M.J., Chin S.L., Rangarajan S., et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016; 388: 761–75.
4. Gray C.S., Scott J.F., French J.M., et al. Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing. 2004; 33: 71–7.
5. Zahra F., Kidwai S.S., Siddiqi S.A., et al. Frequency of newly diagnosed diabetes mellitus in acute ischaemic stroke patients. J Coll Physicians Surg Pak. 2012; 22: 226–9.
6. Eriksson M., Carlberg B., Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. Cerebrovasc Dis. 2012; 34: 153–60.
7. Lei C., Wu B., Liu M., et al. Association between hemoglobin A1C levels and clinical outcome in ischemic stroke patients with or without diabetes. J Clin Neurosci. 2015; 22: 498–503.
8. Wu S., Wang C., Jia Q., et al. HbA1c is associated with increased all-cause mortality in the fi rst year after acute ischemic stroke. Neurol Res. 2014; 36: 444–52.
9. Piernik-Yoder B., Ketchum N. Rehabilitation outcomes of stroke patients with and without diabetes. Arch Phys Med Rehabil. 2013; 94: 1508–12.
10. Mahaffey K.W., Neal B., Perkovic V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018; 137: 323–34.
11. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-57.
12. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-28.
13. Dedov I.I., Shestakova M.V., Mayorov A.Yu. (eds). Standards of specialized diabetes care. 9th ed. Moscow, 2019. DOI: https://doi.org/10.14341/DM221S1 (in Russian)
14. Inzucchi S.E., Khunti K., Fitchett D.H., et al. 19-LB: consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME. Diabetes. 2019; 68 (1).
15. American Diabetes Association Standards of Medical Care in Diabetes - 2018. Update. Diabetes Care. 2019; March.
16. Buehler A.M., Cavalcanti A.B., Berwanger O., et al. Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2013; 31: 147-60.
17. Rathmann W., Kostev K., Gruenberger J.B., et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013; 15: 55-61.
18. Rosenstock J., Kahn S.E., Johansen O.E., et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA Randomized Clinical Trial. JAMA. 2019; 322 (12): 1155-66.
19. Rosenstock J., Perkovic V., Johansen O.E., et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321 (1): 69-79. DOI: https://doi.org/10.1001/jama.2018.18269